The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
 
 
Employment - BioNTech
Stock and Other Ownership Interests - BioNTech
BNT321, a novel monoclonal antibody targeting sialyl Lewis A: Phase 1 monotherapy and combination with mFOLFIRINOX in patients with advanced CA19-9 expressing cancers.
 
Eileen Mary O'Reilly
Consulting or Advisory Role - AstraZeneca; Autem Medical (I); Boehringer Ingelheim; Eisai (I); Exelixis (I); Genentech/Roche (I); Helio Health (I); Incyte (I); Ipsen; Merck; Novartis; QED Therapeutics (I); Yiviva (I); Yiviva (I)
Research Funding - Arcus Ventures (Inst); AstraZeneca/MedImmune (Inst); BioNTech (Inst); Bristol Myers Squibb (Inst); Bristol Myers Squibb (Inst); Celgene (Inst); Genentech (Inst); Helsinn Healthcare (Inst); Puma Biotechnology (Inst); QED Therapeutics (Inst); Roche (Inst); Yiviva (Inst)
(OPTIONAL) Uncompensated Relationships - Thetis Pharma
 
Todd Michael Bauer
Employment - Tennessee Oncology
Consulting or Advisory Role - AVEO; Bayer; Lilly; Pfizer; Sanofi
Speakers' Bureau - Bayer; Lilly
Travel, Accommodations, Expenses - Pfizer
 
Erkut Hasan Borazanci
Consulting or Advisory Role - Boehler Life Science Advice; BPGbio; ClearNote Health; Conjupro Biotherapeutics; Elevation Oncology; NanOlogy; Qurient; TD2; Vivacitus
Research Funding - BioNTech (Inst); Biosplice (Inst); Bristol-Myers Squibb (Inst); Corcept Therapeutics (Inst); Daiichi Sankyo (Inst); Helix BioPharma (Inst); Idera (Inst); Lilly (Inst); Merck (Inst); Minneamrita Therapeutics (Inst); Pharmacyclics (Inst)
 
Meredith Pelster
Honoraria - Castle Biosciences (I)
Consulting or Advisory Role - AstraZeneca (Inst); Bayer (Inst); CytomX Therapeutics (Inst); Daiichi Sankyo (Inst); EMD Serono (Inst); Ipsen (Inst); Novartis (Inst); Pfizer (Inst); Seagen (Inst)
Research Funding - 1200 Pharma (Inst); Actuate Therapeutics (Inst); Agenus (Inst); Arcus Biosciences (Inst); Astellas Pharma (Inst); BeiGene (Inst); BioNTech (Inst); Bristol-Myers Squibb (Inst); Codiak Biosciences (Inst); Compass Therapeutics (Inst); CytomX Therapeutics (Inst); Eisai (Inst); Elevation Oncology (Inst); Exelixis (Inst); Gilead Sciences (Inst); HiberCell (Inst); Immune-Onc Therapeutics (Inst); Leap Therapeutics (Inst); Novartis (Inst); OncXerna Therapeutics (Inst); Panbela Therapeutics (Inst); Revolution Medicines (Inst); SQZ Biotechnology (Inst); Surface Oncology (Inst); Tachyon Therapeutics (Inst); Translational Genomics Research Institute (Inst); TransThera Sciences (Nanjing), Inc. (Inst); ZielBio (Inst)
 
Anna M. Varghese
Consulting or Advisory Role - AstraZeneca (I); Lilly (I); PAIGE (I); Roche (I)
Research Funding - BioMed Valley Discoveries; Bristol-Myers Squibb; Illumina (I); Lilly; Silenseed; Verastem
Travel, Accommodations, Expenses - Roche (I)
 
Wungki Park
Consulting or Advisory Role - Astellas Pharma; Cerner Enviza; onconic therapeutics
Research Funding - Astellas Pharma (Inst); Merck (Inst)
 
Manish R. Patel
Leadership - ION Pharma
Honoraria - Janssen Oncology
Consulting or Advisory Role - Accutar Biotech; Daiichi Sankyo/UCB Japan; Olema Pharmaceuticals
Research Funding - Accutar Biotech (Inst); Accutar Biotech (Inst); Acerta Pharma (Inst); Adagene (Inst); ADC Therapeutics (Inst); Agenus (Inst); Aileron Therapeutics (Inst); Allorion Therapeutics (Inst); Artios (Inst); Artios (Inst); Artios (Inst); Artios (Inst); Astellas Pharma (Inst); AstraZeneca (Inst); Bayer (Inst); Bicycle Therapeutics (Inst); BioNTech (Inst); BioTheryX (Inst); BioTheryX (Inst); Black Diamond Therapeutics (Inst); Black Diamond Therapeutics (Inst); Blueprint Medicines (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb/Celgene (Inst); Celgene (Inst); CicloMed (Inst); Clovis Oncology (Inst); Compugen (Inst); Compugen (Inst); Conjupro Biotherapeutics (Inst); Cullinan Oncology (Inst); cyteir (Inst); Daiichi Sankyo (Inst); Erasca, Inc (Inst); Evelo Therapeutics (Inst); Genentech/Roche (Inst); Gilead Sciences (Inst); GlaxoSmithKline (Inst); H3 Biomedicine (Inst); Hengrui Therapeutics (Inst); Hotspot Therapeutics (Inst); Hutchison MediPharma (Inst); IgM Biosciences (Inst); IgM Biosciences (Inst); Immune-Onc Therapeutics (Inst); Immunitas (Inst); Immunogen (Inst); Incyte (Inst); Jacobio (Inst); Janssen (Inst); Jazz Pharmaceuticals (Inst); Kineta (Inst); Klus Pharma (Inst); Kymab (Inst); Lilly (Inst); Loxo (Inst); LSK BioPharma (Inst); Lycera (Inst); MabSpace Biosciences (Inst); MabSpace Biosciences (Inst); Macrogenics (Inst); Merck (Inst); Millennium (Inst); Mirati Therapeutics (Inst); Moderna Therapeutics (Inst); NGM Biopharmaceuticals (Inst); NGM Biopharmaceuticals (Inst); NGM Biopharmaceuticals (Inst); Novartis (Inst); Novartis (Inst); Novartis (Inst); nurix (Inst); Nurix (Inst); Olema Oncology (Inst); ORIC Pharmaceuticals (Inst); ORIC Pharmaceuticals (Inst); Pfizer (Inst); Pionyr (Inst); Prelude Therapeutics (Inst); Puretech (Inst); PureTech (Inst); PureTech (Inst); Relay Therapeutics (Inst); Relay Therapeutics (Inst); Revolution Medicines (Inst); Ribon Therapeutics (Inst); Ribon Therapeutics (Inst); Samumed (Inst); Seven and Eight Biopharmaceuticals (Inst); Silicon Therapeutics (Inst); Step Pharma (Inst); Syndax (Inst); Syndax (Inst); Synthorx (Inst); Taiho Pharmaceutical (Inst); TeneoBio (Inst); Tesaro (Inst); TopAlliance BioSciences Inc (Inst); Treadwell Therapeutics (Inst); Treadwell Therapeutics (Inst); Treadwell Therapeutics (Inst); Vigeo Therapeutics (Inst); Xencor (Inst); Zymeworks (Inst)
 
Gayle S. Jameson
Employment - Lifecare Centers of America (I)
Honoraria - BroadcastMED
Research Funding - Bristol Myers Squibb Foundation (Inst)
Travel, Accommodations, Expenses - BroadcastMED
 
Mary Larsen
No Relationships to Disclose
 
Kathryn Chin
No Relationships to Disclose
 
Teresa J. Melink
Employment - SciQuus Oncology
Leadership - SciQuus Oncology
Stock and Other Ownership Interests - SciQuus Oncology
 
John Gutheil
Employment - SciQuus Oncology
Leadership - SciQuus Oncology
Stock and Other Ownership Interests - SciQuus Oncology
Patents, Royalties, Other Intellectual Property - Listed as an inventor on a patient from Cleave Biotechnology
 
Elizabeth O'Reilly Cosgrove
No Relationships to Disclose
 
Kristen N. Balogh
Employment - BioNTech
Stock and Other Ownership Interests - BioNTech
Research Funding - BioNTech
Patents, Royalties, Other Intellectual Property - Neon Therapeutics
Travel, Accommodations, Expenses - BioNTech
 
Tim Maiwald
Employment - Avrobio; BioNTech SE
Stock and Other Ownership Interests - Avrobio; BioNTech SE
 
Mark DeMario
Employment - BioNTech
Stock and Other Ownership Interests - BioNTech
 
Ilhan Celik
Employment - BioNTech SE; Merck KGaA
Stock and Other Ownership Interests - BioNTech SE; Merck
Honoraria - BioNTech SE
Patents, Royalties, Other Intellectual Property - BioNTech SE
 
Özlem Türeci
Employment - BioNTech SE
Leadership - BioNTech SE
Stock and Other Ownership Interests - BioNTech SE
Research Funding - BioNTech SE; HI-TRON Mainz
Patents, Royalties, Other Intellectual Property - BioNTech SE; HI-TRON
Travel, Accommodations, Expenses - BioNTech SE
Other Relationship - Association for Cancer Immunotherapy; On the scientific advisory board for HI-TRON
 
Ugur Sahin
Employment - BioNTech SE
Leadership - BioNTech SE
Stock and Other Ownership Interests - BioNTech SE
Research Funding - BioNTech SE
Patents, Royalties, Other Intellectual Property - BioNTech SE; Tron
Travel, Accommodations, Expenses - BioNTech SE
Other Relationship - HI-TRON Mainz; Tron
 
Judy S. Wang
Consulting or Advisory Role - Fusion Pharmaceuticals; Janssen Research & Development; Kanaph Therapeutics; Stemline Therapeutics
Speakers' Bureau - AstraZeneca; Eisai
Research Funding - Adagene (Inst); Agenus (Inst); Artios (Inst); Astellas Pharma (Inst); AstraZeneca (Inst); Bayer Health (Inst); BeiGene (Inst); Bicycle Therapeutics (Inst); BioNTech (Inst); Biosplice (Inst); BioTheryX (Inst); Blueprint Medicines (Inst); Boehringer Ingelheim (Inst); Celgene (Inst); Cullinan Oncology (Inst); cyteir (Inst); Daiichi Sankyo (Inst); Erasca, Inc (Inst); Forty Seven (Inst); Genentech/Roche (Inst); GlaxoSmithKline (Inst); H3 Biomedicine (Inst); Hotspot Therapeutics (Inst); Hutchison MediPharma (Inst); IgM Biosciences (Inst); Immune-Onc Therapeutics (Inst); Immunogen (Inst); Jacobio (Inst); Janssen Research & Development (Inst); Jazz Pharmaceuticals (Inst); Klus Pharma (Inst); Kymab (Inst); Loxo (Inst); LSK BioPharma (Inst); MabSpace Biosciences (Inst); Macrogenics (Inst); Merck (Inst); Metabomed (Inst); Moderna Therapeutics (Inst); NGM Biopharmaceuticals (Inst); Novartis (Inst); Nurix (Inst); Olema Oncology (Inst); ORIC Pharmaceuticals (Inst); Phoenix Pharmaceuticals (Inst); Prelude Therapeutics (Inst); PureTech (Inst); QiLu Pharmaceutical (Inst); Relay Therapeutics (Inst); Revolution Medicines (Inst); Ribon Therapeutics (Inst); Seven and Eight Biopharmaceuticals (Inst); Syndax (Inst); Taiho Pharmaceutical (Inst); TeneoBio (Inst); Tesaro (Inst); TopAlliance BioSciences Inc (Inst); Treadwell Therapeutics (Inst); Xencor (Inst); Zymeworks (Inst)